Autor: |
Razan Mohty, Rama Al Hamed, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Amer Zeidan, Mohamad Mohty |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-16 (2022) |
Druh dokumentu: |
article |
ISSN: |
1756-8722 |
DOI: |
10.1186/s13045-022-01346-9 |
Popis: |
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Molecular and genetic characterization of MDS has led to a better understanding of the disease pathophysiology and is leading to the development of novel therapies. Targeted and immune therapies have shown promising results in different hematologic malignancies. However, their potential use in MDS is yet to be fully defined. Here, we review the most recent advances in therapeutic approaches in MDS, focusing on higher-risk disease. Allogeneic hematopoietic cell transplantation is beyond the scope of this article. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|